Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

577
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
577
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

691
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
691
Glaucoma: Overview01:25

Glaucoma: Overview

771
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
771
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

27
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
27
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

34
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

Ophthalmic research·2026
Same author

Generative Artificial Intelligence-Driven Voice Assistance for Patient Education in Ophthalmology.

JAMA ophthalmology·2026
Same author

Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability.

Ophthalmology and therapy·2026
Same author

Prevalence and patterns of anti-angiogenic treatment discontinuation in neovascular age-related macular degeneration-insights from health claims data.

Eye (London, England)·2026
Same author

Infographic: effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the centre of the macula and good visual acuity (DRCR Protocol V Study).

Eye (London, England)·2026
Same author

Leveraging structured EMR data for efficient patient prescreening: a practical approach to reducing screen-failure rates in Light Touch Trial.

Eye (London, England)·2026

Related Experiment Video

Updated: Sep 14, 2025

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.3K

HOME OPTICAL COHERENCE TOMOGRAPHY-GUIDED MANAGEMENT OF TYPE 3 MACULAR NEOVASCULARIZATION.

Livia Faes1, Nancy Holekamp2, Gidi Benyamini3

  • 1Vitreous Retina Macula Consultants of New York, New York, New York.

Retinal Cases & Brief Reports
|July 23, 2025
PubMed
Summary

Home optical coherence tomography (OCT) enables personalized treatment for type 3 wet age-related macular degeneration (AMD). This approach allows continuous monitoring and optimized anti-angiogenic injections, maintaining stable vision and reducing fluid accumulation.

Keywords:
age-related macular degenerationantivascular endothelial growth factor (VEGF) treatmenthome monitoringhome optical coherence tomography (OCT)type 3 macular neovascularization

More Related Videos

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography
07:23

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography

Published on: March 26, 2020

7.6K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.4K

Related Experiment Videos

Last Updated: Sep 14, 2025

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.3K
Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography
07:23

Retinal Vascular Reactivity as Assessed by Optical Coherence Tomography Angiography

Published on: March 26, 2020

7.6K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.4K

Area of Science:

  • Ophthalmology
  • Medical Imaging
  • Regenerative Medicine

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Type 3 neovascularization (MNV) presents unique challenges in management.
  • Current treatment protocols may not be fully optimized for individual patient needs.

Purpose of the Study:

  • To evaluate the efficacy of home optical coherence tomography (OCT) for personalizing treatment in type 3 MNV.
  • To assess the impact of continuous retinal fluid monitoring on treatment decisions.
  • To explore the potential of patient self-imaging in managing wet AMD.

Main Methods:

  • A prospective trial involving a single patient with type 3 MNV.
  • Utilized home OCT for regular self-imaging over 23.4 weeks.
  • Treatment decisions (anti-angiogenic injections) were guided by home OCT findings and investigator discretion.

Main Results:

  • 143 home OCT measurements were performed, averaging 6.1 per week.
  • Individualized treatment intervals averaged 8 weeks, maintaining 20/20 visual acuity.
  • Home OCT revealed fluid fluctuations and guided injections, with complete intraretinal fluid resolution between treatments.

Conclusions:

  • Home OCT-guided management shows promise for optimizing treatment in type 3 MNV.
  • The neovascular subtype classification (CONAN) can aid in treatment decisions.
  • Further research is needed to understand retinal fluid dynamics in various MNV subtypes.